Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
2002 31
2003 26
2004 30
2005 21
2006 18
2007 30
2008 48
2009 33
2010 35
2011 35
2012 36
2013 26
2014 25
2015 19
2016 11
2017 8
2018 16
2019 13
2020 15
2021 18
2022 10
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

464 results

Results by year

Filters applied: . Clear all
Page 1
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Yokoyama M, et al. Among authors: shimada k. Lancet. 2007 Mar 31;369(9567):1090-8. doi: 10.1016/S0140-6736(07)60527-3. Lancet. 2007. PMID: 17398308 Clinical Trial.
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T. Shimada K, et al. Lancet Oncol. 2020 Apr;21(4):593-602. doi: 10.1016/S1470-2045(20)30059-0. Epub 2020 Mar 11. Lancet Oncol. 2020. PMID: 32171071 Clinical Trial.
Biology and management of primary effusion lymphoma.
Shimada K, Hayakawa F, Kiyoi H. Shimada K, et al. Blood. 2018 Nov 1;132(18):1879-1888. doi: 10.1182/blood-2018-03-791426. Epub 2018 Aug 28. Blood. 2018. PMID: 30154110 Free article. Review.
Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.
Shimada K, Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, Kataoka K, Yuge M, Takagi Y, Kusumoto S, Masaki Y, Ito T, Inagaki Y, Okamoto A, Kuwatsuka Y, Nakatochi M, Shimada S, Miyoshi H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shiozawa Y, Nannya Y, Okabe A, Kohno K, Atsuta Y, Ohshima K, Nakamura S, Ogawa S, Tomita A, Kiyoi H. Shimada K, et al. Blood. 2021 Mar 18;137(11):1491-1502. doi: 10.1182/blood.2020007245. Blood. 2021. PMID: 33512416 Free PMC article.
A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
Kato K, Fujii N, Makita S, Goto H, Kanda J, Shimada K, Akashi K, Izutsu K, Teshima T, Fukuda N, Sumitani T, Nakamura S, Sumi H, Shimizu S, Kakurai Y, Yoshikawa K, Tobinai K, Usui N, Hatake K. Kato K, et al. Among authors: shimada k. Int J Hematol. 2023 Mar;117(3):409-420. doi: 10.1007/s12185-022-03494-7. Epub 2022 Nov 18. Int J Hematol. 2023. PMID: 36399286 Clinical Trial.
464 results